Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.41 |
| ▸ | TSHR | P16473 | 6/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.33 |
| ▸ | CD44 | P16070 | 1/20 | 0.32 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9285279 | 0.80 | TDP1 (0.48) | TDP1MEN1KMT2ACYP3A4ALOX15 | |
| SCHEMBL3981923 | 0.80 | ALDH1A1 (0.48) | TDP1MEN1KMT2ACYP3A4SMN1; SMN2 | |
| SCHEMBL9285276 | 0.79 | POLB (0.62) | TDP1MEN1KMT2ACYP3A4ALOX15 | |
| SCHEMBL3976718 | 0.78 | ALDH1A1 (0.40) | TDP1MEN1KMT2ACYP3A4ALOX15 | |
| SCHEMBL6834129 | 0.77 | HSD17B10 (0.48) | TDP1CYP3A4ALDH1A1TSHRPOLB | |
| Biphenyl SCHEMBL17969155 | 0.75 | HSD17B10 (0.46) | TDP1MEN1KMT2ACYP3A4ALOX15 | |
| SCHEMBL9751003 | 0.75 | TDP1 (0.52) | TDP1MEN1KMT2ACYP3A4ALOX15 | |
| SCHEMBL3321576 | 0.75 | ALDH1A1 (0.48) | TDP1MEN1KMT2ACYP3A4ALOX15 | |
| SCHEMBL2790053 | 0.75 | MAPT (0.45) | TDP1KMT2ACYP3A4SMN1; SMN2TP53 | |
| SCHEMBL11217857 | 0.73 | TDP1 (0.45) | TDP1MEN1KMT2ACYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9763925-B2 | Antibacterial compounds | SUMMIT THERAPEUTICS PLC (GB) | 2017-09-19 | — | — | US | disclosed |
| EP-3095783-A1 | ANTIBACTERIAL COMPOUNDS | Summit Corporation Plc (GB) | 2016-11-23 | — | — | EP | disclosed |
| US-20160184283-A1 | ANTIBACTERIAL COMPOUNDS | SUMMIT (OXFORD) LIMITED (GB) | 2016-06-30 | — | — | US | disclosed |
| EP-2907813-B1 | Antibacterial pharmaceutical compositions | SUMMIT THERAPEUTICS PLC (GB) | 2016-04-27 | — | — | EP | disclosed |
| US-9314456-B2 | Antibacterial compounds | SUMMIT THERAPEUTICS PLC (GB) | 2016-04-19 | — | — | US | disclosed |
| EP-2907813-A1 | Antibacterial Compound | Summit Corporation Plc (GB) | 2015-08-19 | — | — | EP | disclosed |
| US-20150150861-A1 | ANTIBACTERIAL COMPOUNDS | SUMMIT (OXFORD) LIMITED (GB) | 2015-06-04 | — | — | US | disclosed |
| US-8975416-B2 | Antibacterial compounds | SUMMIT CORPORATION PLC (GB) | 2015-03-10 | — | — | US | disclosed |
| EP-2373631-B1 | ANTIBACTERIAL COMPOUNDS | SUMMIT CORP PLC (GB) | 2015-02-25 | — | — | EP | disclosed |
| US-20120020950-A1 | ANTIBACTERIAL COMPOUNDS | SUMMIT CORPORATION PLC | 2012-01-26 | — | — | US | disclosed |
| EP-2373631-A2 | ANTIBACTERIAL COMPOUNDS | Summit Corporation Plc (GB) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010063996-A2 | ANTIBACTERIAL COMPOUNDS | SUMMIT CORPORATION PLC (GB) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160184283-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, RPN2, ALPI | TDP1 4052/4885MEN1 3400/4885KMT2A 4829/4885 |
| US-20120020950-A1 | ANTIBACTERIAL COMPOUNDS | RPN2, MRPL21, ALPI | TDP1 4050/4885MEN1 3476/4885KMT2A 4829/4885 |
| US-20150150861-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, RPN2, ALPI | TDP1 4052/4885MEN1 3400/4885KMT2A 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.